[ET Net News Agency, 13 April 2022] HSBC Global Research lowered its target price for
Hansoh Pharma (03692) to HK$18 from HK$38.1 and maintained its "buy" rating.
The research house said it expects Hansoh Pharma to continue expanding its pipeline,
adding 6-8 new molecules to clinical-stage testing each year. (RC)